Literature DB >> 17457784

[Practical guidelines for the management of osteoporosis--evidence-based and cost-effective].

R Bartl1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457784     DOI: 10.1055/s-2007-979369

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


× No keyword cloud information.
  7 in total

1.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

2.  Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.

Authors:  Akihiko Matsumoto; Masanori Sasaki; Rainer Schmelzeisen; Yukiko Oyama; Yoshihide Mori; Pit Jacob Voss
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  [Secondary osteoporosis: pathogenesis, types, diagnostics and therapy].

Authors:  C Bartl; R Bartl
Journal:  Radiologe       Date:  2011-04       Impact factor: 0.635

4.  [Treatment of osteoporosis according to the "European Guidance 2008". Fracture-oriented--economical--cost-effective].

Authors:  R Bartl
Journal:  Internist (Berl)       Date:  2008-09       Impact factor: 0.743

Review 5.  [Current prevention and treatment strategies for osteoporosis. Fracture-oriented, effective, low side effects and inexpensive].

Authors:  R Bartl; C Bartl
Journal:  Internist (Berl)       Date:  2015-12       Impact factor: 0.743

Review 6.  [Current diagnosis and therapy of osteoporosis on the basis of "European guidance 2008"].

Authors:  R Bartl; R Gradinger
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

7.  [Use of bisphosphonates in orthopedic surgery].

Authors:  R Bartl; C Bartl; R Gradinger
Journal:  Orthopade       Date:  2008-06       Impact factor: 1.004

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.